Research programme: anti-infective mRNA therapeutics - Valera

Drug Profile

Research programme: anti-infective mRNA therapeutics - Valera

Alternative Names: mRNA 1388; mRNA 1850; mRNA Therapeutics - Valera; mRNA Vaccines - Valera

Latest Information Update: 16 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Moderna Therapeutics
  • Developer Moderna Therapeutics; Valera LLC
  • Class RNA; RNA vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants; Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Infections; Parasitic infections; Viral infections; Zika virus infection
  • Research HIV infections

Most Recent Events

  • 07 Sep 2016 Moderna Therapeutics receives grant from the Biomedical Advanced Research and Development Authority (BARDA) for development of an mRNA vaccine for Zika virus infection
  • 07 Sep 2016 Preclinical trials in Zika virus infection in USA (Parenteral) (before September 2016; 9202849)
  • 07 Sep 2016 Moderna Therapeutics announces intention to submit IND to the US FDA in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top